Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.

Niklaus Meier Hendrik Fuchs Katya Galactionova Cedric Hermans Mark Pletscher Matthias E Schwenkglenks

Published in: PharmacoEconomics - open (2024)

Depending on the price, ED can save costs and improve health outcomes of haemophilia patients compared with EHL-FIX prophylaxis, making it a potentially cost-effective alternative. These results are uncertain due to a lack of evidence regarding the long-term effectiveness of ED.

Keyphrases

emergency department
end stage renal disease
newly diagnosed
ejection fraction
randomized controlled trial
chronic kidney disease
systematic review
prognostic factors
patient reported outcomes